Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Cash from Operations (2019 - 2023)

Alx Oncology Holdings' Cash from Operations history spans 5 years, with the latest figure at 39678000.0 for Q4 2023.

  • For Q4 2023, Cash from Operations fell 91.98% year-over-year to 39678000.0; the TTM value through Dec 2023 reached 130364000.0, down 46.11%, while the annual FY2025 figure was 84142000.0, 30.98% up from the prior year.
  • Cash from Operations for Q4 2023 was 39678000.0 at Alx Oncology Holdings, down from 31159000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2874000.0 in Q4 2019 and bottomed at 39678000.0 in Q4 2023.
  • The 5-year median for Cash from Operations is 19055000.0 (2021), against an average of 18446500.0.
  • The largest annual shift saw Cash from Operations crashed 373.73% in 2020 before it soared 42.71% in 2021.
  • A 5-year view of Cash from Operations shows it stood at 2874000.0 in 2019, then plummeted by 373.73% to 13615000.0 in 2020, then dropped by 28.45% to 17488000.0 in 2021, then fell by 18.18% to 20668000.0 in 2022, then plummeted by 91.98% to 39678000.0 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Cash from Operations are 39678000.0 (Q4 2023), 31159000.0 (Q3 2023), and 31711000.0 (Q2 2023).